Combination of radiofrequency ablation and immunotherapy

Francesco F. Fagnoni, Alessandro Zerbini, Guido Pelosi, Gabriele Missale

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The enhancement of immune response against tumor antigens has shown some efficacy when used as a single mode of systemic treatment in patients with late stage disease. Novel strategies of active immunotherapy could be more effective in patients with less advanced disease who receive standard therapies supporting concomitant stimulation of the immune system. Radio-Frequency Ablation (RFA) is a minimally invasive technique which is used as standard local therapy of primary and metastatic liver tumors. Tumor ablation by RFA induces effects important for boosting anti-tumor immune responses. Tumor cell necrosis generates a permanent immunogenic source of tumor antigens. These antigens can be uptaken, processed and presented by dendritic cells for effective immunization without requirement for ex vivo antigen loading. Further immune activation can be originated by RFA through induction of heat shock proteins on tumor cells, acute phase response which causes the release of pro-inflammatory cytokines, and mobilization of antigen presenting cells and effector lymphocytes. Thus, RFA can facilitate immune responses to tumor antigens driven by active immunotherapy. On the other hand, immunotherapy is expected to eradicate residual disease after RFA and prevent tumor recurrences. The combination of RFA and active immunotherapy may well have synergistic effects for cancer treatment.

Original languageEnglish
Pages (from-to)369-381
Number of pages13
JournalFrontiers in Bioscience
Volume13
Issue number1
DOIs
Publication statusPublished - 2008

Fingerprint

Ablation
Immunotherapy
Radio
Tumors
Active Immunotherapy
Neoplasm Antigens
Neoplasms
Cells
Immunization
Antigens
Acute-Phase Reaction
Oncology
Lymphocytes
Immune system
Antigen-Presenting Cells
Therapeutics
Heat-Shock Proteins
Liver
Dendritic Cells
Immune System

Keywords

  • DCs
  • HCC
  • IFN
  • Immunotherapy
  • Interferon,vascular endotelial growth factor
  • Review
  • RFA
  • TAA
  • TNF
  • Tumor necrosis factor
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology
  • Medicine(all)

Cite this

Fagnoni, F. F., Zerbini, A., Pelosi, G., & Missale, G. (2008). Combination of radiofrequency ablation and immunotherapy. Frontiers in Bioscience, 13(1), 369-381. https://doi.org/10.2741/2686

Combination of radiofrequency ablation and immunotherapy. / Fagnoni, Francesco F.; Zerbini, Alessandro; Pelosi, Guido; Missale, Gabriele.

In: Frontiers in Bioscience, Vol. 13, No. 1, 2008, p. 369-381.

Research output: Contribution to journalArticle

Fagnoni, FF, Zerbini, A, Pelosi, G & Missale, G 2008, 'Combination of radiofrequency ablation and immunotherapy', Frontiers in Bioscience, vol. 13, no. 1, pp. 369-381. https://doi.org/10.2741/2686
Fagnoni, Francesco F. ; Zerbini, Alessandro ; Pelosi, Guido ; Missale, Gabriele. / Combination of radiofrequency ablation and immunotherapy. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 1. pp. 369-381.
@article{937901f34a044d5590e4909a3773fbed,
title = "Combination of radiofrequency ablation and immunotherapy",
abstract = "The enhancement of immune response against tumor antigens has shown some efficacy when used as a single mode of systemic treatment in patients with late stage disease. Novel strategies of active immunotherapy could be more effective in patients with less advanced disease who receive standard therapies supporting concomitant stimulation of the immune system. Radio-Frequency Ablation (RFA) is a minimally invasive technique which is used as standard local therapy of primary and metastatic liver tumors. Tumor ablation by RFA induces effects important for boosting anti-tumor immune responses. Tumor cell necrosis generates a permanent immunogenic source of tumor antigens. These antigens can be uptaken, processed and presented by dendritic cells for effective immunization without requirement for ex vivo antigen loading. Further immune activation can be originated by RFA through induction of heat shock proteins on tumor cells, acute phase response which causes the release of pro-inflammatory cytokines, and mobilization of antigen presenting cells and effector lymphocytes. Thus, RFA can facilitate immune responses to tumor antigens driven by active immunotherapy. On the other hand, immunotherapy is expected to eradicate residual disease after RFA and prevent tumor recurrences. The combination of RFA and active immunotherapy may well have synergistic effects for cancer treatment.",
keywords = "DCs, HCC, IFN, Immunotherapy, Interferon,vascular endotelial growth factor, Review, RFA, TAA, TNF, Tumor necrosis factor, VEGF",
author = "Fagnoni, {Francesco F.} and Alessandro Zerbini and Guido Pelosi and Gabriele Missale",
year = "2008",
doi = "10.2741/2686",
language = "English",
volume = "13",
pages = "369--381",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "1",

}

TY - JOUR

T1 - Combination of radiofrequency ablation and immunotherapy

AU - Fagnoni, Francesco F.

AU - Zerbini, Alessandro

AU - Pelosi, Guido

AU - Missale, Gabriele

PY - 2008

Y1 - 2008

N2 - The enhancement of immune response against tumor antigens has shown some efficacy when used as a single mode of systemic treatment in patients with late stage disease. Novel strategies of active immunotherapy could be more effective in patients with less advanced disease who receive standard therapies supporting concomitant stimulation of the immune system. Radio-Frequency Ablation (RFA) is a minimally invasive technique which is used as standard local therapy of primary and metastatic liver tumors. Tumor ablation by RFA induces effects important for boosting anti-tumor immune responses. Tumor cell necrosis generates a permanent immunogenic source of tumor antigens. These antigens can be uptaken, processed and presented by dendritic cells for effective immunization without requirement for ex vivo antigen loading. Further immune activation can be originated by RFA through induction of heat shock proteins on tumor cells, acute phase response which causes the release of pro-inflammatory cytokines, and mobilization of antigen presenting cells and effector lymphocytes. Thus, RFA can facilitate immune responses to tumor antigens driven by active immunotherapy. On the other hand, immunotherapy is expected to eradicate residual disease after RFA and prevent tumor recurrences. The combination of RFA and active immunotherapy may well have synergistic effects for cancer treatment.

AB - The enhancement of immune response against tumor antigens has shown some efficacy when used as a single mode of systemic treatment in patients with late stage disease. Novel strategies of active immunotherapy could be more effective in patients with less advanced disease who receive standard therapies supporting concomitant stimulation of the immune system. Radio-Frequency Ablation (RFA) is a minimally invasive technique which is used as standard local therapy of primary and metastatic liver tumors. Tumor ablation by RFA induces effects important for boosting anti-tumor immune responses. Tumor cell necrosis generates a permanent immunogenic source of tumor antigens. These antigens can be uptaken, processed and presented by dendritic cells for effective immunization without requirement for ex vivo antigen loading. Further immune activation can be originated by RFA through induction of heat shock proteins on tumor cells, acute phase response which causes the release of pro-inflammatory cytokines, and mobilization of antigen presenting cells and effector lymphocytes. Thus, RFA can facilitate immune responses to tumor antigens driven by active immunotherapy. On the other hand, immunotherapy is expected to eradicate residual disease after RFA and prevent tumor recurrences. The combination of RFA and active immunotherapy may well have synergistic effects for cancer treatment.

KW - DCs

KW - HCC

KW - IFN

KW - Immunotherapy

KW - Interferon,vascular endotelial growth factor

KW - Review

KW - RFA

KW - TAA

KW - TNF

KW - Tumor necrosis factor

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=38449111843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449111843&partnerID=8YFLogxK

U2 - 10.2741/2686

DO - 10.2741/2686

M3 - Article

C2 - 17981554

AN - SCOPUS:38449111843

VL - 13

SP - 369

EP - 381

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 1

ER -